Gu, Xiaorong
Tohme, Rita http://orcid.org/0000-0001-6147-9420
Tomlinson, Benjamin
Sakre, Nneha
Hasipek, Metis
Durkin, Lisa
Schuerger, Caroline
Grabowski, Dale
Zidan, Asmaa M.
Radivoyevitch, Tomas http://orcid.org/0000-0002-9701-1851
Hong, Changjin
Carraway, Hetty
Hamilton, Betty
Sobecks, Ronald
Patel, Bhumika
Jha, Babal K. http://orcid.org/0000-0002-7660-5255
Hsi, Eric D.
Maciejewski, Jaroslaw
Saunthararajah, Yogen http://orcid.org/0000-0002-9757-1031
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (P30 CA043703)
Article History
Received: 6 April 2020
Revised: 13 July 2020
Accepted: 22 July 2020
First Online: 7 August 2020
Compliance with ethical standards
:
: Ownership: YS—EpiDestiny. Income: none. Research support: none. Intellectual property: YS—patents around tetrahydrouridine, decitabine and 5-azacytidine (US 9,259,469 B2; US 9,265,785 B2; US 9,895,391 B2), and cancer differentiation therapy (US 9,926,316 B2). The other authors declare that they have no conflict of interest.